Literature DB >> 19121690

Sero-characterization of lipopolysaccharide from Burkholderia thailandensis.

Omar Qazi1, Joann L Prior, Barbara M Judy, Gregory C Whitlock, G Barrie Kitto, Alfredo G Torres, D Mark Estes, Katherine A Brown.   

Abstract

We report the successful purification of lipopolysaccharide (LPS) from Burkholderia thailandensis, a Gram-negative bacterium, closely related to the highly pathogenic organisms B. pseudomallei and B. mallei. Burkholderia thailandensis LPS is shown to cross-react with rabbit and mouse sera obtained from inoculation with B. pseudomallei or B. mallei, respectively. These data suggest that B. thailandensis LPS shares similar structural features with LPS molecules from highly pathogenic Burkholderia species. This information may prove useful in ongoing efforts to develop novel vaccines and/or diagnostic reagents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19121690      PMCID： PMC3656469          DOI： 10.1016/S0035-9203(08)70016-6

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  5 in total

1.  Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.

Authors:  Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

2.  Rapid multiplex immunofluorescent assay to detect antibodies against Burkholderia pseudomallei and taxonomically closely related nonfermenters.

Authors:  Hirotoshi Iihara; Takashi Niwa; Mohammad Monir Shah; Pham Hong Nhung; Sun Xiao Song; Masahiro Hayashi; Kiyofumi Ohkusa; Yoshinori Itoh; Sou-ichi Makino; Takayuki Ezaki
Journal:  Jpn J Infect Dis       Date:  2007-07       Impact factor: 1.362

3.  Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies.

Authors:  H Stanley Kim; Mark A Schell; Yan Yu; Ricky L Ulrich; Saul H Sarria; William C Nierman; David DeShazer
Journal:  BMC Genomics       Date:  2005-12-07       Impact factor: 3.969

4.  Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Toll-like receptor 4 complexes.

Authors:  Paul J Brett; Mary N Burtnick; D Scott Snyder; Jeffrey G Shannon; Parastoo Azadi; Frank C Gherardini
Journal:  Mol Microbiol       Date:  2006-12-05       Impact factor: 3.501

5.  Lipopolysaccharide from nonvirulent Ara+ Burkholderia pseudomallei isolates is immunologically indistinguishable from lipopolysaccharide from virulent Ara- clinical isolates.

Authors:  N Anuntagool; P Intachote; V Wuthiekanun; N J White; S Sirisinha
Journal:  Clin Diagn Lab Immunol       Date:  1998-03
  5 in total
  8 in total

1.  Development of reagents and assays for the detection of pathogenic Burkholderia species.

Authors:  Omar Qazi; Mridula Rani; Annie J Gnanam; Thomas W Cullen; Christopher M Stead; Haley Kensing; Kate McCaul; Sarah Ngugi; Joann L Prior; Alexandria Lipka; Judit M Nagy; C Whitlock Gregory; Barbara M Judy; Sarah V Harding; Richard W Titball; Sachdev S Sidhu; M Stephen Trent; G Barrie Kitto; Alfredo Torres; D Mark Estes; Brent Iverson; George Georgiou; Katherine A Brown
Journal:  Faraday Discuss       Date:  2011       Impact factor: 4.008

2.  Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine.

Authors:  Alfredo G Torres; Anthony E Gregory; Christopher L Hatcher; Heather Vinet-Oliphant; Lisa A Morici; Richard W Titball; Chad J Roy
Journal:  Vaccine       Date:  2014-12-19       Impact factor: 3.641

3.  Differential susceptibility of inbred mouse strains to Burkholderia thailandensis aerosol infection.

Authors:  Lisa A Morici; Julie Heang; Tim Tate; Peter J Didier; Chad J Roy
Journal:  Microb Pathog       Date:  2009-10-21       Impact factor: 3.738

4.  Development of vaccines against burkholderia pseudomallei.

Authors:  Natasha Patel; Laura Conejero; Melanie De Reynal; Anna Easton; Gregory J Bancroft; Richard W Titball
Journal:  Front Microbiol       Date:  2011-09-27       Impact factor: 5.640

5.  The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide.

Authors:  Apichai Tuanyok; Joshua K Stone; Mark Mayo; Mirjam Kaestli; Jeffrey Gruendike; Shalamar Georgia; Stephanie Warrington; Travis Mullins; Christopher J Allender; David M Wagner; Narisara Chantratita; Sharon J Peacock; Bart J Currie; Paul Keim
Journal:  PLoS Negl Trop Dis       Date:  2012-01-03

6.  Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.

Authors:  Dina A Moustafa; Jennifer M Scarff; Preston P Garcia; Sara K B Cassidy; Antonio DiGiandomenico; David M Waag; Thomas J Inzana; Joanna B Goldberg
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  Outer Membrane Vesicle Vaccines from Biosafe Surrogates Prevent Acute Lethal Glanders in Mice.

Authors:  Michael H Norris; Mohammad S R Khan; Sunisa Chirakul; Herbert P Schweizer; Apichai Tuanyok
Journal:  Vaccines (Basel)       Date:  2018-01-10

8.  A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.

Authors:  Anthony E Gregory; Barbara M Judy; Omar Qazi; Carla A Blumentritt; Katherine A Brown; Andrew M Shaw; Alfredo G Torres; Richard W Titball
Journal:  Nanomedicine       Date:  2014-09-03       Impact factor: 5.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.